SSTR2 and neuroendocrine neoplasm: Therefore, further optimization is required to combine an ABD and JR11 to obtain a long-acting SSTR2 antagonist with an adequate biodistribution and pharmacokinetic profile for safe and efficient radionuclide therapy of neuroendocrine tumors.